Kempner Capital Management Inc. Raises Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Kempner Capital Management Inc. increased its holdings in Zimmer Biomet Holdings, Inc. by 47.7% during the 2nd quarter, owning a total of 58,496 shares, which are valued at approximately $5.34 million.
• Zimmer Biomet has been issuing dividends, with the most recent quarterly dividend of $0.24 per share scheduled to be paid on October 31st, representing a 1.0% yield.
• The company reported earnings of $2.07 per share for the last quarter, exceeding analyst expectations of $1.98 and showing a 7.0% revenue increase compared to the previous year.

Kempner Capital Management Inc. increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 47.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,496 shares of the medical equipment provider's stock after buying an additional 18,896 shares during the period. Zimmer Biomet comprises approximately 2.9% of Kempner Capital Management Inc.'s holdings, making the stock its 14th largest holding. Kempner Capital Management Inc.'s holdings in Zimmer Biomet were worth $5,335,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in ZBH. Janney Montgomery Scott LLC grew its holdings in Zimmer Biomet by 0.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider's stock worth $2,903,000 after acquiring an additional 118 shares in the last quarter. Curbstone Financial Management Corp boosted its stake in shares of Zimmer Biomet by 3.4% during the first quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider's stock valued at $483,000 after purchasing an additional 140 shares in the last quarter. Brooklyn Investment Group increased its holdings in Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider's stock valued at $52,000 after buying an additional 145 shares during the period. Roberts Wealth Advisors LLC raised its stake in Zimmer Biomet by 0.8% in the first quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider's stock worth $2,093,000 after buying an additional 152 shares in the last quarter. Finally, Wesbanco Bank Inc. lifted its holdings in Zimmer Biomet by 0.8% during the first quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider's stock worth $2,265,000 after buying an additional 163 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.70% of the company's stock.

Zimmer Biomet Stock Performance

ZBH opened at $100.29 on Wednesday. The company has a market cap of $19.87 billion, a P/E ratio of 24.40, a price-to-earnings-growth ratio of 2.34 and a beta of 0.68. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The firm's 50-day moving average price is $100.35 and its 200-day moving average price is $99.32. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's payout ratio is presently 23.36%.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of analyst reports. Redburn Partners set a $130.00 price target on Zimmer Biomet in a report on Thursday, September 18th. Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Stifel Nicolaus increased their price target on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a "buy" rating in a research report on Friday, September 19th. Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They issued a "buy" rating and a $130.00 price objective on the stock. Finally, Rothschild Redb raised shares of Zimmer Biomet to a "strong-buy" rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $113.16.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.